|
| Friday, November 12, 2021 |
|
|
Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer's Disease (CTAD) Conference |
| Eisai Co., Ltd. and Biogen Inc. announced today results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across multiple statistical models in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). more info >> |
|
|
Eisai: Introduction of Plasma-based Biomarker Screening to Facilitate Identification of Subjects for Phase 3 Ahead 3-45 Trial Presented at Clinical Trials on Alzheimer's Disease (CTAD) Conference |
| Eisai Co., Ltd. and Biogen Inc. announced a presentation about exploring the use of plasma-based biomarkers in the Phase 3 AHEAD 3-45 study of lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody. more info >> |
|
|
バイオジェンとエーザイ、ADUHELMの臨床第III相試験におけるアルツハイマー病の臨床症状の悪化抑制とバイオマーカーとの正の相関を示す新しいデータを第14回アルツハイマー病臨床試験会議にて発表 |
| バイオジェンとエーザイ、ADUHELM(TM)の臨床第III相試験におけるアルツハイマー病の臨床症状の悪化抑制とバイオマーカーとの正の相関を示す新しいデータを第14回アルツハイマー病臨床試験（CTAD）会議において発表 more info >> |
|
|
エーザイとバイオジェン、レカネマブの臨床第IIb相試験の臨床効果に関する新たな解析結果を第14回アルツハイマー病臨床試験会議にて発表 |
| エーザイとバイオジェン、レカネマブの臨床第IIb相試験の臨床効果に関する新たな解析結果を第14回アルツハイマー病臨床試験会議にて発表 more info >> |
|
|
エーザイとバイオジェン、レカネマブの臨床第III相試験の対象者を同定する、初めての血漿中バイオマーカーによる被験者スクリーニングの導入について第14回アルツハイマー病臨床試験会議にて発表 |
| エーザイとバイオジェン、レカネマブの臨床第III相試験（AHEAD 3-45試験）の対象者を同定する、初めての血漿中バイオマーカーによる被験者スクリーニングの導入について第14回アルツハイマー病臨床試験（CTAD）会議において発表 more info >> |
|
| Thursday, November 11, 2021 |
|
|
エーザイ、レカネマブの臨床第IIb相201試験のコアならびにOLE試験より５年間にわたる臨床バイオマーカーと安全性データに関する最新の知見を第14回アルツハイマー病臨床試験（CTAD）会議において発表 |
| エーザイ、レカネマブの臨床第IIb相201試験のコアならびにOLE試験より５年間にわたる臨床バイオマーカーと安全性データに関する最新の知見を第14回アルツハイマー病臨床試験（CTAD）会議において発表 more info >> |
|
|
Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2b Study Core and Open-Label Extension |
| Eisai Co., Ltd. and Biogen Inc. announced today results of new clinical, biomarker and safety assessments of brain amyloid reduction and five-year clinical status of people living with early Alzheimer's disease (AD) from the lecanemab Phase 2b 201 and the open-label extension (OLE) studies. more info >> |
|
| Tuesday, November 9, 2021 |
|
|
エーザイ、DIAN-TUは優性遺伝アルツハイマー病に対するタウ標的療法を評価する次世代臨床試験において、その基礎療法となる抗アミロイド療法としてレカネマブを選定 |
| エーザイ、DIAN-TUは優性遺伝アルツハイマー病に対するタウ標的療法を評価する次世代臨床試験において、その基礎療法となる抗アミロイド療法としてレカネマブを選定 more info >> |
|
|
Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer's Disease |
| Eisai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has an agreement with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to amend the clinical study (Tau NexGen) design to include a background anti-amyloid agent. more info >> |
|
| Wednesday, October 12, 2016 |
|
|
Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 |
| Eisai Co., Ltd. announced today that a presentation on the results of a Phase Ib clinical study of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in combination with the anti-PD-1 antibody pembrolizumab developed by Merck & Co., Inc., known as MSD outside the United States and Canada, in patients with selected solid tumors was given at the European Society for Medical Oncology (ESMO) Congress held from October 7 to 11. more info >> |
|
|
|
|
